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Abstract
To determine the efficacy and safety of risedronate in patients
with knee osteoarthritis (OA), the British study of risedronate in
structure and symptoms of knee OA (BRISK), a 1-year
prospective, double-blind, placebo-controlled study, enrolled
patients (40–80 years of age) with mild to moderate OA of the
medial compartment of the knee. The primary aims were to
detect differences in symptoms and function. Patients were
randomized to once-daily risedronate (5 mg or 15 mg) or
placebo. Radiographs were taken at baseline and 1 year for
assessment of joint-space width using a standardized
radiographic method with fluoroscopic positioning of the joint.
Pain, function, and stiffness were assessed using the Western
Ontario and McMaster Universities (WOMAC) OA index. The
patient global assessment and use of walking aids were
measured and bone and cartilage markers were assessed. The
intention-to-treat population consisted of 284 patients. Those
receiving risedronate at 15 mg showed improvement of the
WOMAC index, particularly of physical function, significant
improvement of the patient global assessment (P < 0.001), and
decreased use of walking aids relative to patients receiving the
placebo (P = 0.009). A trend towards attenuation of joint-space
narrowing was observed in the group receiving 15 mg
risedronate. Eight percent (n = 7) of patients receiving placebo
and 4% (n = 4) of patients receiving 5 mg risedronate exhibited
detectable progression of disease (joint-space width ≥  25% or
≥  0.75 mm) versus 1% (n = 1) of patients receiving 15 mg
risedronate (P  = 0.067). Risedronate (15 mg) significantly
reduced markers of cartilage degradation and bone resorption.
Both doses of risedronate were well tolerated. In this study,
clear trends towards improvement were observed in both joint
structure and symptoms in patients with primary knee OA
treated with risedronate.
Introduction
Osteoarthritis (OA) is a chronic, progressive disease that par-
ticularly affects weight-bearing joints such as hips and knees.
The entire joint is affected by a complex combination of degra-
dative and reparative processes, which alter the anatomy and
function of articular cartilage, subchondral bone, and other
joint tissues. Of the joints affected, knee OA in particular is a
major cause of morbidity, often resulting in knee replacement
[1-3]. Moreover, costs associated with OA are high – in the
USA alone in 1991, the annual cost of knee replacements was
estimated to be more than one billion dollars [4]. OA is nor-
mally the result of an interplay between systemic (e.g. age,
obesity) and local (e.g. sports injury) factors that affect the
joints of the body. Radiographic evidence has shown that joint-
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space narrowing (a surrogate marker for articular cartilage
[5]), sclerosis of the subchondral bone, and the presence of
osteophytes are typical structural features of OA.
Current therapies for OA are largely aimed at providing symp-
tom relief, and include a wide range of analgesics (e.g. nons-
teroidal anti-inflammatory drugs and cyclooxygenase-2
agents). In contrast, only limited data are available about ther-
apies that modify the course of the disease or affect joint struc-
ture. Historically, OA has been considered a disease of the
cartilage, but more recent evidence suggests that subchron-
dral bone is also involved in the pathogenesis, in both disease
initiation and progression. For example, increased local bone
turnover, decreased bone mineral content and stiffness, and
decreased trabecular numbers have been observed in OA
subchondral bone structure compared with normal bone [6-8].
There is an increased level of interest in subchondral bone as
a therapeutic OA target, and, in particular, the possibility that
drugs affecting bone metabolism might alter the progression
of knee and hip OA.
The Duncan-Hartley guinea pig model is a widely used spon-
taneous model of OA progression [9]. Several recent OA
studies have evaluated this model for the effects of the antire-
sorptive agents bisphosphonates. For example, a comparative
analysis of multiple bisphosphonates showed that only the
group of nitrogen-containing bisphosphonates with pyridinyl
sidechains demonstrated significant effects on the cartilage,
although not all of these proved effective [10]. In a separate
study using the guinea pig OA model, the pyridinyl bisphos-
phonate risedronate was shown to slow disease progression,
as measured by the size and severity of cartilage lesions and
the size of osteophytes, by up to 40% [11]. Based upon these
preclinical studies, a clinical trial was performed in order to
evaluate the effects of risedronate in patients with mild to mod-
erate knee OA. The primary end points were changes in symp-
toms and function, with secondary end points of changes in
joint structure or in markers of joint structure.
Materials and methods
Study design and selection of patients
The British Study of Risedronate in Structure and Symptoms
of Knee OA (BRISK) was a 1-year prospective, double-blind,
placebo-controlled study conducted in 10 centres in the UK.
Male and female subjects aged 40 to 80 years with mild to
moderate medial-compartment knee OA, diagnosed accord-
ing to the clinical and radiological criteria of the American Col-
lege of Rheumatology [12], were recruited into the trial.
OA in at least one knee, designated the signal knee, was
required to meet the following clinical and radiographic inclu-
sion criteria. Clinical inclusion criteria were the presence of
daily knee pain for at least 1 month out of the 3 months pre-
ceding the study, with at least one of the following: age >50
years, morning knee stiffness of <30 minutes, or knee crepitus.
The radiographic criteria for inclusion were a joint-space width
(JSW) of 2 to 4 mm in the medial tibiofemoral compartment in
the semiflexed anterior–posterior (AP) view of the signal knee
and a narrower width than in the lateral compartment of the
same knee. Patients were also required to have at least one
osteophyte in either the medial or the lateral compartment of
the tibiofemoral joint. Major exclusion criteria were the pres-
ence of rheumatic diseases that could be responsible for sec-
ondary OA; use of intra-articular hyaluronic acid in the signal
knee; knee injury or diagnostic arthroscopy of the signal knee
in the 6 months preceding enrollment; a history of knee sur-
gery (including arthroscopy requiring an incision of internal
joint components) in the signal knee at any time; intra-articular
corticosteroids in the 3 months preceding enrollment; the
presence of non-OA causes of knee pain in the signal knee
(e.g. anserine bursitis, fibromyalgia, or osteonecrosis); and the
use of bisphosphonates within the 12 months preceding
enrollment.
The subjects gave their written, informed consent before
entering the study, which was conducted in accordance with
the International Conference on Harmonization (ICH) guide-
lines for Good Clinical Practice (GCP) and was approved by
the UK Multicentre Research Ethical Committee (MREC).
Treatment assignment
The subjects were randomly assigned in a 1:1:1 ratio to one of
three arms to receive risedronate at 5 mg or 15 mg or placebo
once daily for 1 year. Before randomization, patients were
stratified according to their current use of oestrogen or a
selective oestrogen receptor modulator.
The subjects were instructed to take their study medication
with at least 120 mL of water, 30 minutes before breakfast, or,
if the medication was taken later in the day, at least 2 hours
before or after food intake and at least 30 minutes before bed-
time. They were instructed to take their study medication while
they were upright and not to lie down for at least 30 minutes
afterwards.
Symptom outcome measures
The outcome instrument for evaluation of risedronate efficacy
on symptoms of OA was the Western Ontario and McMaster
Universities (WOMAC) OA index [13]. The visual analogue
scale (VAS) of the index was used, in which patients assessed
each question using a 100-mm scale, with a higher score rep-
resenting greater symptom severity. The total index score for
the signal knee corresponded to the weighted composite of
the 24 question scores standardized to a 100-point scale.
Scores were also determined for the subscales of pain (5
questions), stiffness (2 questions), and physical function (17
questions). Other symptom outcome measures included the
patient global assessment (PGA) of disease, consumption of
pain medication, and the use of walking aids. For the PGA,
patients answered the following question using a VAS:Available online http://arthritis-research.com/content/7/3/R625
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"Considering all the ways your OA affects you, how have you
been in the last 48 hours?" Patients marked values on a scale
from 0 to 100 mm.
A step-down reduction in the use of pain medication was
effected 5 days before all symptom evaluations. Patients were
provided with approximately 30 tablets each of paracetamol
(500 mg) and diclofenac (50 mg) to be used as the only pain
medication 3 to 5 days before the baseline assessment and at
visits at months 3, 6, and 12 (the exit visit). No pain medica-
tions were to be used 2 days before the scheduled evaluation
date or on the day itself, with the exception of low-dose acetyl-
salicylic acid (<350 mg/day) for cardiac protection. Rescue
analgesia was permitted during the study except for the 2-day
washout period before each visit.
Structure outcome measures
The outcome measure for assessment of joint structural
changes was the mean change from baseline values in mini-
mum JSW of the medial compartment of the knee. Radio-
graphs of the knee were taken at baseline and at 1 year using
a standardized radiographic method with fluoroscopic posi-
tioning of the joint in a semiflexed position [14,15]. By the use
of this technique, the anterior and posterior rims of the tibia
were aligned (to within 1 mm) for reproducible positioning.
Radiographs were subjected to extensive quality control at the
radiographic facility before dispatch to the Central Analysis
Center [15]. Radiographs were read centrally and their quality
control was rechecked before computer software was used to
obtain the radiographic magnification. This was determined
from measurement of a metal ball placed at the head of the fib-
ula at the time of radiography and was used to adjust the com-
puterized measurement obtained of the minimum medial
compartment JSW [15]. The test–retest standard deviation of
the difference between radiographs taken 2 days apart for this
technique was approximately 0.2 mm, based upon repeat
measurements in 199 subjects [15]. A retrospective analysis
was performed taking into account the precision of the instru-
ment. Retrospectively, clinically meaningful disease progres-
sion was defined as joint-space narrowing of ≥  0.75 mm or a
≥  25% loss from baseline values. The ≥  0.75-mm value is
almost four times the 0.2-mm standard deviation observed for
the x-ray method.
Structure–symptom relation
The relation between knee OA symptoms and radiographic
joint-space narrowing was assessed retrospectively; the mean
change in symptom scores between baseline to month 12 of
the total WOMAC score and pain and function subscales was
compared with the magnitude of change in JSW over the
study period.
Bone and cartilage markers
Early-morning fasting urine and serum samples were collected
at baseline and at months 3, 6, and 12 for assessment of mark-
ers of bone and cartilage turnover. Bone resorption was
assessed by measurement of urinary levels of the N-terminal
crosslinking telopeptide of type I collagen (NTX-I, Osteomark;
OrthoClinical Diagnostics, High Wycombe, Bucks, UK) [16].
Bone formation was assessed by measurement of bone-spe-
cific serum alkaline phosphatase (Ostase, Beckman-Coulter,
San Diego, CA, USA) [17] and cartilage degradation was
assessed by measurement of urinary levels of C-terminal
crosslinking telopeptide of type II collagen (CTX-II, Cartilaps,
Nordic Bioscience, Herlev, Denmark) [18]. The intra-assay
and interassay coefficients of variation were lower than 10%.
Evaluation of safety
Patient-reported adverse events (AEs) were recorded
throughout the study. AEs were categorized using the Coding
Symbols for Thesaurus of Adverse Reaction Terms (COS-
TART®) coding dictionary. Clinical laboratory measurements
for safety monitoring were made throughout the study. Serious
AEs were defined as any that resulted in death; were life
threatening; resulted in hospitalization; resulted in persistent
or significant disability or incapacity; or were judged to be
medically significant.
Upper-GI AEs included the following symptoms and condi-
tions: substernal chest pain; duodenitis; dyspepsia; dys-
phagia; oesophagitis; gastritis; bleeding gastritis; gastro-
oesophageal reflux; oesophageal bleeding; GI bleeding; hae-
matemesis; melena; abdominal pain; ulcers (duodenal,
oesophageal, peptic, gastric); bleeding ulcers (duodenal, pep-
tic, gastric); perforated ulcers (duodenal, peptic, gastric); per-
forated and bleeding ulcers (duodenal, peptic, gastric); and
reactivated ulcers (duodenal, peptic, gastric).
Statistical analysis
To ensure 80% power to detect a 20% effect of risedronate
treatment versus placebo with respect to pain modification
(quantified according to the WOMAC pain subscale, assum-
ing a standard deviation of 70 mm on a 0- to 500-mm scale),
a 1-year dropout rate of 20%, and a type I error rate of 5%
without adjustment for two comparisons with placebo control,
the sample size requirement was 100 patients per treatment
group.
Analyses were undertaken on the intention-to-treat (ITT) pop-
ulation. This was defined as all randomized patients who
received at least one dose of study medication. All statistical
analyses were performed using a two-sided statistical test
with a type-I-error rate of 0.05. Baseline characteristics were
compared using Fisher's exact test for categorical variables
and the Kruskal–Wallis test for continuous variables. Extended
Mantel–Haenszel tests with pooled centres as strata were
used for end points with categorical responses. Analysis of
variance (ANOVA) methods were used. Symptom analyses
were adjusted for baseline value (PGA < WOMAC total or
subscale value, as appropriate), pooled study centres,Arthritis Research & Therapy    Vol 7 No 3    Spector et al.
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baseline use of oestrogen or selective oestrogen receptor
modulators, gender, age, body mass index, and baseline JSW.
Mean JSW analyses were adjusted for pooled study centres,
baseline use of oestrogen or selective oestrogen receptor
modulators, gender, age, body mass index, and baseline JSW
as covariates. Each risedronate group was compared with the
placebo group. For walking aids, the percentages were com-
pared with placebo using the Cochran–Mantel–Haenszel test
after adjusting for pooled centres. Individual AEs and the pro-
portion of clinically meaningful JSW progressors were ana-
lysed using Fisher's exact test.
The WOMAC scores were calculated in accordance with the
WOMAC User's Guide [19]. The total scores were composed
of subscales weighted as follows: pain = 42%, stiffness =
21%, and function = 37% [19]. For each subscale, the
reported response was the patient's average. If at least two
pain items, both stiffness items, or more than four physical
function items were omitted, or if the patient's response was
unclear, the items were regarded as invalid and the relevant
subscale was not included.
Results
Patients
Two hundred and eighty-five patients were considered eligible
for the study and were randomized to treatment. Of these, 284
received at least one dose of study medication and were
included in the ITT population, and 231 (81%) completed the
study (placebo, n = 80; risedronate at 5 mg, n = 80; risedro-
nate at 15 mg, n = 71) (Fig. 1). The number of patients who
completed the study and the reasons for withdrawal were sim-
ilar across treatment groups. Table 1 shows the baseline char-
acteristics for the ITT population. These were similar between
treatment groups; the average age of the patients was 63.3
years. There were no significant differences in the use of con-
comitant analgesics between treatment groups. Patients'
compliance during study treatment, based on pill counts, was
≥  83% and was comparable in the three treatment groups.
Symptom outcome measures
There was an improvement from baseline values in the symp-
tom outcome measure of total WOMAC scores (weighted and
unweighted) (unweighted not shown) and the subscales for all
treatment groups (Fig. 2). The group given risedronate at 15
mg showed a trend towards improvement from baseline val-
ues, although the differences were not statistically significant
(P values from 0.10 to 0.33).
Assessment of PGAs revealed a statistically significant
improvement with risedronate at 15 mg compared with pla-
cebo at 1 year (-19.4 for risedronate at 15 mg versus -5.7 for
placebo, P < 0.001) (Fig. 3). Although all treatment groups
showed a significant improvement from baseline values at 3
months, the improvement in the group receiving risedronate at
15 mg continued to increase with time, whereas the level of
improvement with placebo or risedronate at 5 mg did not show
any further improvement after 6 months.
Analysis of the use of walking aids during study treatment
showed a statistically significant difference in the proportion of
patients who used walking aids in patients treated with risedr-
onate at 15 mg (7 patients, 4% reduction) compared with pla-
cebo (21 patients, 8% increase) (P = 0.009) at 12 months
compared with the proportion of patients that had reported
using a walking aid during the previous year.
Figure 1
Disposition of patients with knee osteoarthritis in a controlled, randomized trial of risedronate Disposition of patients with knee osteoarthritis in a controlled, randomized trial of risedronate.
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Structure outcome measures
Assessment of the mean change from baseline values in mini-
mum JSW in the medial compartment of the tibiofemoral joint
at 1 year showed that there was a trend for patients receiving
risedronate at 5 mg (JSW -0.08 ± 0.44 mm) or 15 mg (JSW -
0.06 ± 0.25 mm). The change was greater in patients receiv-
ing placebo (JSW -0.12 ± 0.42 mm) compared with baseline
values. Overall, the difference between treatment groups in
loss of JSW at 12 months was not statistically significant (P =
0.275). The loss in JSW from baseline values was statistically
significant only in the placebo group (P < 0.05).
Table 1
Baseline characteristics of the intention-to-treat (ITT) population with osteoarthritis of the knee
Risedronate
Characteristic Placebo (n = 98) 5 mg/day (n = 96) 15 mg/day (n = 90) P
Age (years) 63.2 (0.82) 62.9 (0.90) 63.8 (0.88) 0.652a
Height (cm) 164.3 (0.90) 165.3 (0.97) 165.1 (0.93) 0.614a
Body mass index (kg/m2) 29.2 (0.38) 29.0 (0.40) 29.2 (0.42) 0.799a
Sex (no. (%)) 0.307b
Male 34 (35%) 40 (42%) 41 (46%)
Female 64 (65%) 56 (58%) 49 (54%)
Post-menopausal (no. (%)) 54 (84%) 49 (88%) 43 (88%) 0.985b
Years since menopause 14.4 (1.22) 16.5 (1.57) 17.4 (1.42) 0.273a
Oestrogen or SERM use (no. (%)) 18 (28%) 15 (27%) 10 (20%) 0.380b
Race (no.) 0.385b
Asian Oriental 1 0 0
A s i a n  I n d i a n 102
Caucasian 96 96 88
Joint-space width (mm) 3.03 (0.05) 2.95 (0.05) 3.01 (0.06) 0.577a
WOMAC – weighted total score 50.3 (2.0) 46.1 (2.0) 49.4 (2.4) 0.281a
Use of walking aids (no. (%)) 16 (16) 22 (23) 12 (13) 0.224b
uCTX-II (ng/mmol creatinine) 312.5 (19.9) 328.9 (29.7) 340.1 (24.0) 0.748a
uNTX-I (nmol/mmol creatinine) 40.3 (2.8) 42.3 (4.5) 38.6 (2.2) 0.954a
Unless indicated otherwise, values are means (standard errors of the mean). aKruskal–Wallis test; bFisher exact test. SERM, selective oestrogen 
receptor modulator; uCTX-II, urinary C-terminal crosslinking telopeptide of type II collagen; uNTX-I, urinary N-terminal crosslinking telopeptide of 
type I collagen; WOMAC, Western Ontario and McMaster Universities osteoarthritis index.
Table 2
Summary of adverse events (no. (%)) in patients with osteoarthritis who received risedronate or placebo
Placebo Risedronate
(n = 98) 5 mg/day (n = 96) 15 mg/day (n = 90)
Patients with AEs 94 (96%) 95 (99%) 84 (93%)
Dropouts due to AEs 12 (12%) 7 (7%) 10 (11%)
Overall GI AEs 15 (15%) 16 (17%) 7 (8%)
Abdominal pain 6 (6%) 7 (7%) 3 (3%)
Dyspepsia 7 (7%) 7 (7%) 3 (3%)
Gl disorder 3 (3%) 1 (1%) 1 (1%)
AE, adverse event; GI, gastrointestinal.Arthritis Research & Therapy    Vol 7 No 3    Spector et al.
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In terms of detectable progression (i.e. loss of JSW ≥  25% or
≥  0.75 mm), the analysis of the distribution of change from
baseline values in JSW at 1 year showed a greater presence
of detectable progression in the placebo (8%) and risedronate
(5 mg) (4%) (P = 0.36) groups than in the risedronate (15 mg)
group (1%) (P = 0.067). The patients with JSW loss of >0.75
mm included none of the patients treated with risedronate at
15 mg and 6% of the patients treated with placebo (P  =
0.060). Similarly, only 1% of the patients treated with risedro-
nate at 15 mg but 7% of the patients treated with placebo had
>25% loss of JSW (P = 0.12).
Structure–symptom relation
Figure 4 shows the relation between structure and symptoms
for this population of patients. The mean WOMAC total score
and the scores on the pain and function subscales increased
(i.e. symptom severity increased) with increasing loss of JSW.
In the group of patients with any loss of JSW, the mean
changes of the WOMAC total score and the scores on the
pain and function subscales at 1 year were -5.9 mm, -4.6 mm,
and -6.3 mm, respectively, indicating that these symptoms
were not increasing overall. In contrast, for the subset of
patients with a loss in JSW of 40% or more, the corresponding
mean changes were +1.4 mm, +6.0 mm, and +2.3 mm,
indicating increased symptom severity in these patients con-
current with narrowing of their knee-joint space.
Markers of biochemical turnover
Risedronate treatment significantly reduced markers of carti-
lage degradation (Fig. 5) and bone resorption compared with
placebo. At 1 year, treatment with risedronate at 15 mg signif-
icantly decreased mean urinary CTX-II values, by -22.8% ±
5.35; urinary NTX-I was reduced by -32.9% ± 4.92 relative to
baseline values (P < 0.05). Dose-dependent effects were also
observed with the 5-mg dose compared with placebo, but to
a lesser magnitude. This finding is consistent with the known
pharmacologic effect of risedronate on bone turnover. At 1
year, CTX-II and NTX-I values in the placebo group were sig-
nificantly higher than those in the risedronate 15-mg group
(14.5% ± 5.4 and 17.2% ± 4.9 higher, respectively). Signifi-
cant decreases in bone alkaline phosphatase were observed
in the risedronate groups compared with placebo. At 1 year,
the mean decreases in the groups receiving risedronate at 15
mg and 5 mg were 29.1% ± 2.6 and 19.5% ± 2.5, respec-
tively, compared with a mean decrease of 2.7% ± 2.5 in the
placebo group (P < 0.001).
Safety
The frequencies of AEs were similar in the two treatment
groups (Table 2). There were no clinically meaningful
differences between groups in the percentage of patients with
AEs in any body system and there were no significant differ-
ences in routine clinical chemistry parameters between the
risedronate groups and the placebo group. The numbers of
patients who dropped out of the study because of AEs were
similar. Overall, 34 patients reported a total of 53 serious AEs.
Investigators considered four serious AEs as possibly related
to study treatment; two of these (rash and diarrhea) were in
patients treated with placebo and two (anaemia and increased
general joint pain) were in patients treated with risedronate at
5 mg.
Table 2 provides a summary of adverse events for the ITT pop-
ulation and the frequency of the overall GI AEs and the most
common upper-GI AEs. Forty-seven upper-GI events were
reported in 38 patients, of which abdominal pain and dyspep-
sia were the most frequently reported. The majority of the
upper-GI AEs occurred in patients with a history of GI disease;
there were no significant differences between the groups
given risedronate and the group given placebo in the inci-
dence of upper-GI AEs in these patients.
Discussion
Increased evidence of the role of bone in both the initiation and
progression of OA has resulted in an interest in drugs that
affect bone metabolism and might slow or even halt the proc-
ess of joint degeneration [6]. The early findings reported here
suggest that the bisphosphonate risedronate may have dis-
ease-modifying effects in patients with knee OA. A recent
cross-sectional study also suggests an association between
antiresorptive treatments (oestrogen or bisphosphonate) and
improved symptoms and/or decreased bone marrow abnor-
malities [20].
Positive trends were observed with risedronate treatment with
regard to symptomatic improvement, as assessed by the
Figure 2
Changes in mean values at 12 months from baseline measures in  patients with osteoarthritis Changes in mean values at 12 months from baseline measures in 
patients with osteoarthritis. Patients were given risodronate (Ris) or pla-
cebo. Scores were the weighted composite of the 24 question scores 
on the visual analogue scale (1 to 100 mm) of the Western Ontario and 
McMaster Universities (WOMAC) osteoarthritis index or its subscales 
for pain, stiffness, and physical function. Vertical lines represent stand-
ard errors of the mean. P values refer to risedronate (15 mg) vs base-
line values.Available online http://arthritis-research.com/content/7/3/R625
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WOMAC index. Treatment with risedronate at 15 mg resulted
in a consistent trend in improvement in WOMAC scores,
whereas the group receiving placebo showed less improve-
ment. The group receiving risedronate at 15 mg showed a sig-
nificant improvement in the PGA of OA compared with
placebo. Similarly, the percentage of patients who used a
walking aid during the study decreased in the group treated
with risedronate at 15 mg, contrasting with an increase in the
placebo group. While the differences in JSW among the
groups were not significant, there was a trend for less loss in
the risedronate (15 mg) than in the placebo group. When the
data were analysed in a post hoc manner to identify patients
with detectable progression (i.e. approximately four times the
precision of the measurement), 8% of patients receiving
placebo and 1% of patients receiving 15 mg risedronate were
found to exhibit this degree of progression. Additionally, rise-
dronate significantly reduced levels of bone resorption and
cartilage degradation, as assessed by NTX-I and CTX-II mark-
ers, respectively.
Despite these encouraging results, they were not confirmed in
multicentre studies of risedronate treatment for 2 years using
a similar protocol [21]. The following provides perspectives
comparing the two studies. In our study, there was a dose-
dependent trend for improvement in the WOMAC score. In the
2-year North American study, which enrolled 1,232 patients
with knee OA, the placebo effect was approximately twice that
observed in our study, and was comparable to the magnitude
of change observed in the group given 15 mg risedronate in
our study. Both studies showed significant decreases in CTX-
II, the marker of cartilage degradation, but these were not
associated with an attenuation of joint-space loss This lack of
association may be related to the length of observation in
these studies. Reijman and colleagues [22] observed 1,235
men and women with OA, followed up over an average period
of 6.6 years. The subjects with baseline CTX-II levels in the
highest quartile had a sixfold risk of progression of knee OA,
defined as a decrease in JSW ≥  2 mm, in comparison with
subjects in the lowest quartile [22]. This suggests that an
enriched population of subjects with an elevated rate of carti-
Figure 3
Changes in mean patient global assessment after risedronate or placebo in osteoarthritis Changes in mean patient global assessment after risedronate or placebo in osteoarthritis. Vertical lines represent standard errors of the mean. Ris, 
risedronate.
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Figure 4
Relation between WOMAC scores and minimum percentage change in  JSW after 1 year in patients with osteoarthritis Relation between WOMAC scores and minimum percentage change in 
JSW after 1 year in patients with osteoarthritis. Scores were the 
weighted composite (1 to 100 mm) of the Western Ontario and 
McMaster Universities (WOMAC) osteoarthritis index or its subscales 
for pain and physical function. JSW, joint-space width.
10
8
6
4
2
0
–2
–4
–6
–8
Minimum JSW % change
C
h
a
n
g
e
f
r
o
m
b
a
s
e
l
i
n
e
(
m
m
)
WOMAC total mean
WOMAC pain mean
WOMAC function mean
0% –10% –20% –30% –40% –50%
n = 146 n =5 0 n =1 6 n =7 n =5 n =5Arthritis Research & Therapy    Vol 7 No 3    Spector et al.
R632
lage loss combined with a longer study period may be required
in order to observe significant treatment effects.
Our study is one of the first to suggest a correlation between
symptoms and structure in OA, although preliminary results
with doxycycline in the treatment of obese women with knee
OA have reported a significant reduction in the proportion of
follow-up visits in which a clinically significant increase in pain
occurred, favouring treatment over placebo, and coinciding
with a decrease in joint-space narrowing [23]. This finding is
important, because it runs contrary to previous results, which
have suggested a poor correlation between these disease
features [24,25]. The limitations of our study include the small
number of patients (n = 10) with the greatest loss of JSW
(>40%), for observations of concurrent increase in joint-space
narrowing and WOMAC symptom severity scores. One
possible explanation for discrepancies between the current
study and previous studies is the difference in radiographic
methodologies used. Several radiographic techniques have
been described for measuring JSW in the knee. We used a
highly standardized, fluoroscopic technique in which the knee
was semiflexed. Recent studies have compared different radi-
ograph imaging methods [26,27]. The results highlighted the
importance of medial tibial plateau alignment with the central
x-ray beam and showed that the standard clinical view of a
standing extended knee is subject to considerable variability.
In contrast, the fluoroscopic technique is well validated and is
less variable in test-retest performance [15,28]. Further stud-
ies are required to further explore the possible correlation
between symptoms and structure observed in our study. If val-
idated, this relation may allow physicians to use the assess-
ment of pain, perhaps in combination with a biomarker such as
CTX-II, as a surrogate for other measures of disease
progression
Conclusion
This study is one of the first to show a correlation between
symptoms and joint structure changes in knee OA. While our
findings were suggestive of a beneficial effect of risedronate
treatment on preservation of bone and cartilage, these trends
seen in this study have not been observed in larger, multicoun-
try cohorts.
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